The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors

Bursa Postgraduate Hospital

Status: Completed

Conditions: Contrast Agents and Oral Factor Xa Inhibitor

Treatments: Drug: computerized tomography

Study type: Observational

Funder types: Other

Identifiers

NCT04611386

Bursa Yüksek İhtisas EAH

Details and patient eligibility

About

The aim of this study is to evaluate the effect of iohexol as a contrast agent on the anticoagulant activity of oral factor Xa inhibitors.

Full description

The study included 65 people who underwent contrast computerized tomography (CT). The study patients were divided into 4 groups. Patients in group 1 were using rivaroxaban (20 patients), patients in group 2 were using apixaban (20 patients), patients in group 3 were using edoxaban (20 patients), and group 4 was the control group (5 volunteers). Iohexol (60 ml) was used as a contrast agent. Two tubes were used to collect 2 ml of blood from the patients at 4 hours after the drug dose (rivaroxaban, apixaban, or edoxaban) and 1 hour after the contrast CT (CT was performed 3 hours after the drug was taken). In the control group, at any time and 1 hour after contrast CT, 2 tubes of 2 ml of blood were collected. The anticoagulant properties of rivaroxaban, apixaban, and edoxaban were evaluated using anti-factor Xa levels.

Enrollment: 65 patients

Sex: All

Ages: 21 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. the use of oral factor Xa inhibitors (patients with nonvalvular AF and CHA2DS2-VASc Score ≥2),
2. age of 21-80 years,
3. no contraindications for anticoagulation use,
4. GFR greater than 30,
5. volunteering to participate in the study, and
6. patients who needed to use contrast agent (iohexol) for CT examination. -

Exclusion criteria

1. coagulopathy,
2. severe hepatic insufficiency,
3. chronic systemic or inflammatory diseases,
4. patients lighter than 60 kg,
5. malignancy,
6. creatinine value above 1.5 mg/dl, and
7. not providing consent to participate in the study -

Trial design

65 participants in 4 patient groups

rivaroxaban group

Description:

20 rivaroxaban using patients

Treatment:

Drug: computerized tomography

apixaban group

Description:

20 apixaban using patients

Treatment:

Drug: computerized tomography

edoxaban group

Description:

20 edoxaban using patients

Treatment:

Drug: computerized tomography

control group

Description:

5 control group patients

Treatment:

Drug: computerized tomography